Paradigm Medical Industries Inc. introduced its electrophysiology instrument (Glaid-PERG) for the early detection of glaucoma.
Paradigm Medical Industries Inc. introduced its electrophysiology instrument (Glaid-PERG) forthe early detection of glaucoma.
"All research and studies indicate the [diagnostic device] is the earliest means of detectingcellular losses attributed to glaucoma and other ocular ailments," said Raymond Cannefax,Paradigm Medical's chief executive officer. An agreement was signed earlier this year with LACEElettronica srl, Rome, for the exclusive distribution of the instrument.
The device has provided high-test repeatability and a high level of accuracy in clinicalstudies at major U.S. and European glaucoma centers, as well as universities and researchcenters, the company said. Ongoing research indicates possible testing applications for ocularailments other than glaucoma.
"We are excited about the impact the new instrument will have-not only in our industry, but inmedical benefits to those who will be diagnosed early [with suspected glaucoma]," Cannefaxsaid. "Early diagnosis will help reduce vision loss and help preserve sight."
Paradigm Medical also introduced a prototype version of its redesigned autoperimetry system(LD400). The system measures patient visual fields to determine the severity of glaucoma and toaid in managing the disease.
For more information, visit Paradigm Medical Industries at booth 755.